4.6 Editorial Material

Accelerated Approval Is Not Conditional Approval Insights From International Expedited Approval Programs

Journal

JAMA ONCOLOGY
Volume 8, Issue 3, Pages 335-336

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jamaoncol.2021.6854

Keywords

-

Categories

Ask authors/readers for more resources

This viewpoint compares the US FDA's accelerated approval pathway for drugs and biologics with similar programs developed by other international regulatory health authorities.
This Viewpoint compares the US Food and Drug Administration's accelerated approval pathway for drugs and biologics with similar programs developed by other international regulatory health authorities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available